Product Application

metabolic diseases
继PD-1、GLP-1之后，ACSL5能否成为下一个重磅炸弹级靶点？
Could ACSL5 be the next blockbuster target after PD-1 and GLP-1?
发布时间 2026-02-12
Cross-disciplinary breakthrough from fatty acid metabolism to precision medicine: In the treatment of metabolic diseases and malignant tumors, a molecule called ACSL5 (acyl-CoA synthetase long-chain family member 5) is quietly becoming a focus of attention in the pharmaceutical industry.
View details
  • ACSL5
  • Youai protein
  • malignant tumors
  • metabolic diseases
Total 1
  • 1
Go to
UA
Link：
Products
Application
Cell FactorTarget Proteins
Custom Services
Custom Protein Expression ServicesCustom SPR Services
About Us
PromotionTechnical ArticlesProduct ApplicationFAQsCitationsAbout Us
We Media：
Facebook Linkedin YouTube X Thraeds Pinterest
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
 Business license (three certificates in one)
Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.